Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

Madrigal Pharmaceuticals (MDGL) announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated ...

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

Blocking the enzyme ACMSD can significantly reduce damage caused by metabolic liver disease according to a new study.

Metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as "non-alcoholic fatty liver disease" — ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Genflow Biosciences PLC on Tuesday said it has secured EUR4 million in funding from the Wallonia region in Belgium, to support its gene therapy development work. The London-based biotechnology company ...